Form 4: Astria Therapeutics Executive Granted Stock Options

Benjamin Harshbarger, Chief Legal Officer of Astria Therapeutics, was granted stock options for 262,500 shares on March 21, 2025.

Summary

• On March 25, 2025, a Form 4 filing was submitted to the SEC regarding Benjamin Harshbarger, Chief Legal Officer of Astria Therapeutics, Inc.
• The filing reports that Mr. Harshbarger was granted stock options to purchase 262,500 shares of Astria Therapeutics common stock on March 21, 2025.
• The exercise price of the options is $6.41 per share.
• The options vest over a four-year period, starting with 25% vesting on February 13, 2026, and the remainder vesting in equal monthly installments over the following three years.
• The options expire on March 20, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation, which is neither particularly positive nor negative.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation component for executives in publicly traded companies.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
• The vesting schedule and exercise price are generally in line with industry standards for similar-sized companies.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, indicating that the company is investing in its leadership.
• Employees may be motivated by the fact that executives are incentivized to improve the company's performance.

Key Dates

Keywords

stock options, Form 4, Astria Therapeutics, ATXS, insider trading, executive compensation, Benjamin Harshbarger, Chief Legal Officer